Jane Street Group LLC Increases Stake in 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT)

Jane Street Group LLC raised its position in 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) by 143.7% during the fourth quarter, according to its most recent filing with the SEC. The institutional investor owned 210,824 shares of the company’s stock after purchasing an additional 124,312 shares during the period. Jane Street Group LLC owned 0.46% of 4D Molecular Therapeutics worth $1,174,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Decheng Capital LLC lifted its stake in 4D Molecular Therapeutics by 0.5% in the 4th quarter. Decheng Capital LLC now owns 400,000 shares of the company’s stock worth $2,228,000 after purchasing an additional 2,165 shares in the last quarter. PNC Financial Services Group Inc. raised its holdings in shares of 4D Molecular Therapeutics by 66.1% during the 4th quarter. PNC Financial Services Group Inc. now owns 9,124 shares of the company’s stock worth $51,000 after acquiring an additional 3,630 shares during the period. Rhumbline Advisers raised its holdings in shares of 4D Molecular Therapeutics by 5.3% during the 4th quarter. Rhumbline Advisers now owns 73,431 shares of the company’s stock worth $409,000 after acquiring an additional 3,675 shares during the period. American Century Companies Inc. raised its holdings in shares of 4D Molecular Therapeutics by 12.9% during the 4th quarter. American Century Companies Inc. now owns 38,785 shares of the company’s stock worth $216,000 after acquiring an additional 4,429 shares during the period. Finally, Nebula Research & Development LLC raised its holdings in shares of 4D Molecular Therapeutics by 37.4% during the 4th quarter. Nebula Research & Development LLC now owns 23,064 shares of the company’s stock worth $128,000 after acquiring an additional 6,277 shares during the period. Hedge funds and other institutional investors own 99.27% of the company’s stock.

4D Molecular Therapeutics Stock Up 1.3%

NASDAQ FDMT opened at $3.85 on Wednesday. 4D Molecular Therapeutics, Inc. has a 52-week low of $2.24 and a 52-week high of $28.93. The business’s 50-day moving average price is $3.28 and its 200 day moving average price is $5.04. The firm has a market cap of $178.35 million, a P/E ratio of -1.35 and a beta of 2.87.

4D Molecular Therapeutics (NASDAQ:FDMT) last released its quarterly earnings results on Thursday, May 8th. The company reported ($0.86) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.84) by ($0.02). As a group, analysts anticipate that 4D Molecular Therapeutics, Inc. will post -2.84 earnings per share for the current year.

Analysts Set New Price Targets

Several research firms have recently commented on FDMT. Royal Bank of Canada reduced their price target on 4D Molecular Therapeutics from $39.00 to $35.00 and set an “outperform” rating on the stock in a report on Monday, March 3rd. The Goldman Sachs Group reduced their price target on shares of 4D Molecular Therapeutics from $51.00 to $44.00 and set a “buy” rating on the stock in a research report on Friday, May 9th. Bank of America reduced their price target on shares of 4D Molecular Therapeutics from $42.00 to $40.00 and set a “buy” rating on the stock in a research report on Monday, March 10th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of 4D Molecular Therapeutics in a research report on Saturday, May 10th. Finally, HC Wainwright restated a “buy” rating and issued a $36.00 price objective on shares of 4D Molecular Therapeutics in a report on Monday, March 3rd. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and seven have issued a buy rating to the stock. Based on data from MarketBeat.com, 4D Molecular Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus price target of $29.56.

About 4D Molecular Therapeutics

4D Molecular Therapeutics, Inc, a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology.